PSYCH up2date, Table of Contents PSYCH up2date 2023; 17(06): 465-471DOI: 10.1055/a-2089-3960 Schritt für Schritt Ketamininfusionstherapie zur Behandlung von Depressionen – Schritt für Schritt Authors Florian Müller-Dahlhaus Michael Junginger Wolfgang Kelsch Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Ketamin ist ein seit vielen Jahrzehnten klinisch eingesetztes, intravenös oder intramuskulär verabreichtes Anästhetikum mit starker analgetischer Wirkung. Seit etwa zwei Jahrzehnten werden Ketamininfusionen zur Depressionsbehandlung off-Label eingesetzt. Dabei kommen niedrigere, sub-anästhetische Dosen von Ketamin zur Anwendung. Randomisiert-kontrollierte Studien und Metaanalysen stützen die antidepressive Wirksamkeit. Letter to this article:Leserbrief zu: Ketamininfusionstherapie zur Behandlung von Depressionen – Schritt für SchrittPSYCH up2date 2024; 18(03): 191-192DOI: 10.1055/a-2250-4785 Full Text References Literatur 1 Berman RM, Cappiello A, Anand A. et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354 2 Zarate Jr CA, Singh JB, Carlson PJ. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864 3 Diazgranados N, Ibrahim L, Brutsche NE. et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802 4 Dean RL, Hurducas C, Hawton K. et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev 2021; 9: CD011612 5 Dean RL, Marquardt T, Hurducas C. et al. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database Syst Rev 2021; 10: CD011611 6 Bahji A, Vazquez GH, Zarate Jr CA. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord 2021; 278: 542-555 7 Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 2018; 23: 801-811 8 Sanacora G, Frye MA, McDonald W. American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74: 399-405 9 Le TT, Di Vincenzo JD, Teopiz KM. et al. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Res 2021; 306: 114231 10 Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol 2015; 30: 152-163